{"id":1713,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ceftriaxone\/"},"modified":"2023-06-25T19:40:54","modified_gmt":"2023-06-25T19:40:54","slug":"ceftriaxone","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ceftriaxone\/","title":{"rendered":"Ceftriaxone"},"content":{"rendered":"

<\/p>\n

Ceftriaxone<\/h1>\n

CLINICAL USE<\/h3>\n

Antibacterial agent<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

1 g daily (severe infections: 2\u20134 g daily)Gonorrhoea: single dose 250 mg IM<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :661.6 (as sodium salt)<\/li>\n
  • %Protein binding                           :85\u201395<\/li>\n
  • %Excreted unchanged in urine     : 40\u201360<\/li>\n
  • Volume of distribution (L\/kg)       :0.12\u20130.18<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :6\u20139\/14.7
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function Maximum 2 g daily
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Not dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HD                     :Not dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Dose as in GFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :Unknown dialysability. 2 g every 12\u201324 hours1CVVhd\/HDFLikely dialysability. 2 g every 12\u201324 hours1
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anticoagulants: effects of coumarins may be enhanced<\/li>\n
  • Ciclosporin: may cause increased ciclosporin levels
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n<\/li>\n
  • Bolus 250 mg: IV \u2013 5mL water for injection; IM \u2013 1 mL 1% lidocaine hydrochloride<\/li>\n
  • Bolus 1 g: IV \u2013 10 mL water for injection; IM \u2013 3.5 mL 1% lidocaine hydrochloride<\/li>\n
  • Infusion: 2 g in 40 mL of calcium-free solution, e.g. sodium chloride 0.9%, glucose 5%<\/li>\n
  • Incompatible with calcium containing solutions, e.g. Hartmann\u2019s, Ringer\u2019s
    \n

    Route<\/h4>\n

    IV, IM, SC<\/p>\n

    Rate of Administration<\/h4>\n

    Bolus: over 2\u20134 minutes Infusion: over at least 30 minutes<\/p>\n

    Comments<\/h4>\n

    Doses of 50 mg\/kg or over should be given by slow IV infusion<\/li>\n

  • For IM injection: doses greater than 1 g should be divided and injected at more than one site
    \n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Calcium ceftriaxone has appeared as a precipitate in urine, or been mistaken as gallstones in patients receiving higher than recommended doses<\/li>\n
  • Contains 3.6 mmol sodium per gram of ceftriaxone<\/li>\n
  • Information from the company shows that the bioavailability of SC administration is equivalent to IV. The maximum amount able to be given in a single SC injection is 500 mg dissolved in 2 mL lidocaine 1%. Administration was said to be tolerable<\/li>\n","protected":false},"excerpt":{"rendered":"

    Ceftriaxone CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1713","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1713"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1713\/revisions"}],"predecessor-version":[{"id":2832,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1713\/revisions\/2832"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}